ABBV News and Press, AbbVie Inc. From 06/20/24

2024-06-20 09:27:33 ET On June 20, 2024, AbbVie Inc. (NYSE:ABBV) announced that it has received FDA approval for expanding the use of its interleukin-23 (IL-23) inhibitor, Skyrizi, to treat adults with moderate to severe ulcerative colitis. This approval is a significant milestone, ...

2024-06-20 08:46:01 ET USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – This year’s 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) has now come and gone, but not without increasing hope for...

2024-06-20 08:41:00 ET The power of compounding is very real. It is a process that takes time, as dividend investing is not about year 1 dividend income, but rather about year 10+. In today's video, we will look at the power of compounding and 10 awesome dividend stocks that offer both grow...

AbbVie Appoints Roxanne S. Austin as Lead Independent Director of the Board of Directors PR Newswire Ms. Austin assumes role from Glenn F. Tilton, who will continue to serve as an independent director NORTH CHICAGO, Ill. , June 20, 2024 /PRNewswi...

2024-06-20 06:53:11 ET Summary Corvus Pharmaceuticals has shown positive growth and maturity over the past six months, with new leadership and increased clinical trial activity. The company is expanding its label and IP developments, with trials in oncology and immunology, as well...

2024-06-20 06:38:57 ET More on AbbVie AbbVie: 5 Reasons That Make A Buy Case AbbVie, Inc. (ABBV) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) AbbVie: Turnaround Lurking After The Correction Pain (Upgrade) ALS therapy market seen increas...

U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease PR Newswire Approval supported by two Phase 3 clinical trials that evaluated SKYRIZI ® for the treatment of moderate to se...

2024-06-18 17:37:24 ET Summary AbbVie's weak stock price performance in the past quarter is in no way an indication of the progress it has made in recent months. Turnaround in revenue growth following Humira's patent expiration is now evident and recent acquisitions could bolster ...

2024-06-18 14:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-17 15:37:41 ET Summary For dividend growth investing, is growth more important than valuation? 49 stocks are valued based on Historical and Future Fair Valuations as well as analyst estimates. 49 stocks are further evaluated based on past dividend growth and future pro...